Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

Sariol, Carlos A.; Serrano-Collazo, Crisanta; Ortiz, Edwin J.; Pantoja, Petraleigh; Cruz, Lorna; Arana, Teresa; Atehortua, Dianne; Pabon-Carrero, Christina; Espino, Ana M.

doi:10.3390/v13122405

Cited by 4 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe Covid-19 disease and worse outcomes have been associated with comorbidities, particularly among cases with Delta and Kappa coronavirus strains (29). A high case fatality rate (40%) has been reported among Covid-19 patients with diabetes and cardiovascular diseases (26).…”

Section: Discussionmentioning

confidence: 99%

Determinants of Covid-19 vaccine uptake among the elderly aged 58 years and above in Kericho County, Kenya: Institution based cross sectional survey

Anino

Wandera²,

Masimba

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Hesitancy to Covid-19 vaccine is a global challenge despite the compelling evidence of the value of vaccine in preventing disease and saving lives. It is suggested that context-specific strategies can enhance acceptability and decrease hesitancy to Covid-19 vaccine. Hence, the study determined uptake and determinants of Covid-19 vaccine following a sustained voluntary vaccination drive by Kenyan government. Method We conducted institution based cross-sectional survey of 1244 elderly persons aged 58 to 98 years in the months of January, February and March, 2022. A multinomial logistic regression analysis was used to investigate determinants of Covid 19 vaccine uptake. The predictor variables included socioeconomic and demographic characteristics, convenience and ease of access of the vaccine, collective responsibility, complacency and the three dimensions of confidence; trust in safety, trust in decision makers and delivery system. The findings are reported as the adjusted odd ratio (AOR) at 95% confidence interval (CI). Significant level was considered at p <0.05. Result The results from the multinomial logistic regression analysis indicated that advanced age and presence of chronic disease were associated with increased odds of doubt on Covid 19 vaccine, while long distance from vaccination centers was associated with increased odds of delay in vaccination. Conclusion Overall, the findings of this study have provided valuable insights into the factors influencing vaccine hesitancy among the elderly population in Kenya and will inform the development of targeted interventions to increase vaccine acceptance and uptake in this population. Key terms: vaccine hesitancy; determinants; delay; refuse

show abstract

Section: Discussionmentioning

confidence: 99%

Determinants of Covid-19 vaccine uptake among the elderly aged 58 years and above in Kericho County, Kenya: Institution based cross sectional survey

Anino

Wandera²,

Masimba

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Following incubation, samples were added to a 96-well plate coated with human ACE-2 protein. Since this is an inhibition assay, color intensity is inversely proportional to the amount of neutralizing antibodies present in samples [10,12].…”

Section: Neutralizing Antibodies Against Sars-cov-2 Variants Of Concernmentioning

confidence: 99%

Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose

et al. 2022

Self Cite

View full text Add to dashboard Cite

Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine’s effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose can neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)]. Fifty-six subjects with IBD and 12 healthy subjects were recruited. Ninety percent of patients with IBD (49/56) received biologics and/or immunomodulatory therapy. Twenty-four subjects with IBD did not develop effective neutralizing capability against the Omicron variant. Seventy percent (17/24) of those subjects received anti-tumor necrosis factor therapy [10 = adalimumab, 7 = infliximab], two of which had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and more extensive studies are needed to evaluate optimal immunity.

show abstract

“…Following incubation, samples were added to a 96 well plate coated with human ACE-2 protein. Since this is an inhibition assay, color intensity is inversely proportional to the amount of neutralizing antibodies present in samples[10][11].This test was performed on SARS-CoV-2 Wild type and seven SARS-CoV-2 variants of concern: Alpha, Beta, Gamma, Epsilon, Kappa, Delta, and Omicron. A result of ≥ 30% in…”

mentioning

confidence: 99%

Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine Dose

López-Marte¹,

Soto-González²,

Ramos-Tollinchi³

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Management of inflammatory bowel disease (IBD) often relies on biological and immunomodulatory agents for remission through immunosuppression, raising concerns regarding the SARS-CoV-2 vaccine's effectiveness. The emergent variants have hindered the vaccine neutralization capacity, and whether the third vaccine dose has the capacity to neutralize SARS-CoV-2 variants in this population remains unknown. This study aims to evaluate the humoral response of SARS-CoV-2 variants in patients with IBD 60 days after the third vaccine dose [BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)].56 su bjects with IBD and 12 healthy subjects were recruited. 90% of patients with IBD (49/56) were receiving biologics and/or immunomodulatory therapy. 24 subjects with IBD did not develop effective neutralizing capability against the Omicron variant. 70% (17/24) of those subjects were receiving anti-Tumor Necrosis Factor therapy [10= adalimumab, 7= infliximab], two of them had a history of COVID-19 infection, and one subject did not develop immune neutralization against three other variants: Gamma, Epsilon, and Kappa. All subjects in the control group developed detectable antibodies and effective neutralization against all seven SARS-CoV-2 variants. Our study shows that patients with IBD might not be protected against SARS-CoV-2 variants, and larger studies are needed to evaluate optimal immunity.

show abstract

Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population

Cited by 4 publications

References 56 publications

Determinants of Covid-19 vaccine uptake among the elderly aged 58 years and above in Kericho County, Kenya: Institution based cross sectional survey

Determinants of Covid-19 vaccine uptake among the elderly aged 58 years and above in Kericho County, Kenya: Institution based cross sectional survey

Inefficient Induction of Neutralizing Antibodies against SARS-CoV-2 Variants in Patients with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy after Receiving a Third mRNA Vaccine Dose

Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine Dose

Contact Info

Product

Resources

About